Halozyme Therapeutics (HALO) Stock Forecast & Price Target
Score
Halozyme Therapeutics, Inc. price target
| HALO | |
|---|---|
| Low | $90.00 |
| Average | $110.00 |
| High | $130.00 |
| Upside vs current price | +9.7% |
The average target of $110.00 is +9.7% versus the current HALO price of $100.27.
Halozyme Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 2 |
| Buy | 5 |
| Hold | 2 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
9 analysts cover HALO.
Halozyme Therapeutics, Inc. EPS and revenue estimates
The estimate table for the Halozyme Therapeutics, Inc. keeps 2026 EPS $8.62, 2027 EPS $10.42, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $8.62 | $1.88B |
| 2027 | $10.42 | $2.10B |
Is Halozyme Therapeutics, Inc. a buy or sell?
Of the 9 analysts covering Halozyme Therapeutics, Inc., 7 rate it a buy (2 strong buy and 5 buy), 2 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The HALO consensus label is Buy, beside 7 buy-side ratings and 0 sell-side ratings.
The average target of $110.00 implies +9.7% versus the current price of $100.27.
the Halozyme Therapeutics, Inc. closes with 7 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Halozyme Therapeutics, Inc. forecast
Between the HALO low of $90.00 and the high of $130.00, the average target is $110.00.
From today's $100.27 print, the HALO average target is +9.7% away.
Most of the HALO coverage agrees: 7 of 9 analysts are on the buy side, 2 are at hold, and 0 are on the sell side, and the published consensus is Buy.
HALO has both upgrades (1) and downgrades (0) in the recent window.
HALO targets have been marked up: $130.00 across the last month versus $114.17 across the last quarter.
HALO coverage is thin at 9 analysts, and one revision moves the average.
Halozyme Therapeutics, Inc. forecast questions
What is the HALO price target?
The published range for HALO is $90.00 to $130.00, with an average of $110.00. That average is +9.7% versus the current price of $100.27.
Is Halozyme Therapeutics, Inc. a buy or sell?
Of the 9 analysts covering Halozyme Therapeutics, Inc., 7 rate it a buy, 2 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for HALO is 7 on the buy side, 2 at hold, and 0 on the sell side.
What is the EPS estimate for Halozyme Therapeutics, Inc.?
Analyst EPS estimates for Halozyme Therapeutics, Inc.: 2026 $8.62, 2027 $10.42.
What is the revenue estimate for Halozyme Therapeutics, Inc.?
Analyst revenue estimates for Halozyme Therapeutics, Inc.: 2026 $1.88B, 2027 $2.10B.
How many analysts cover HALO?
9 analysts cover HALO. Their consensus on HALO is Buy, across those 9.